ISRCTN06257223已完成不适用
Early Metabolic Changes with Thiazide or Beta Blocker Therapy for Essential Hypertensio
Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)0 个研究点目标入组 78 人开始时间: 2005年9月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Non-diabetic patients who are diagnosed as having essential hypertension will be recruited.
- •We will be comparing the two most commonly used drugs to treat hypertension, atenolol and bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced.
- •We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study. The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded.
- •The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period.
- •At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 1 and 2 hours.
- •Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is < 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.
- •The doses of drugs to be used, while commonly used for angina and oedema, are higher than now commonly used for hypertension. We expect them to be well tolerated during short term use. These doses have also been chosen because they will enable genetic studies top be performed subsequently in a large number of patients.
- •Prof M Brown and Clinical Pharmacology Unit team has experience of many research studies in the treatment of hypertension. The design of this study has been derived partly from previous experience from these studies and from patient suggestions from these studies.
排除标准
- •1. Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.
- •2. Any patient who is intolerant of these medications will be excluded from the study.
研究者
相似试验
进行中（未招募）
1 期
EARLY METABOLIC CHANGES WITH THIAZIDE OR BETA BLOCKER THERAPY FOR ESSENTIAL HYPERTENSION (MAIN STUDY). - METABOLIC CHANGES WITH THIAZIDE OR BETA BLOCKER THERAPYESSENTIAL HYPERTENSIOEUCTR2004-004329-90-GBCAMBRIDGE UNIVERSITY HOSPITALS FOUNDATION NHS TRUST
进行中（未招募）
1 期
STUDY TITLE: - Early Metabolic Changes with Thiazide or Beta blocker Therapy for Essential Hypertension – open label extension phase with the potassium sparing diuretic- Amiloride.Essential hypertensionEUCTR2007-005655-42-GBCambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
已完成
不适用
Metabolic Effect of Combined Telmisartan and Nifedipine CR Therapy in Patients with Essential HypertensioEssential Hypertension without metabolic diseaseJPRN-UMIN000007720Kochi Medical School16
进行中（未招募）
1 期
Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with normal male chromosome set and Disorder of Sex Developement due to complete androgen insensitivity syndrome (CAIS)The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to loss of function of androgens.MedDRA version: 14.1Level: PTClassification code 10056292Term: Androgen insensitivity syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-021790-37-DEniversitätsklinikum Schleswig-Holstein, Campus Lübeck30
已完成
3 期
Comparison of clinical and metabolic effects of testosterone and estrogens in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)E34.5Androgen resistance syndromeDRKS00003136niversitätsklinikum Schleswig-Holstein, Campus Lübeck, kaufmännischer Vorstand26